Acute Crit Care.  2023 Feb;38(1):144-148. 10.4266/acc.2021.00829.

Successful treatment of propofol-related infusion syndrome in critically ill patient receiving low-dose propofol infusion: a case report

• Park N
• Ha TS

• KMID: 2540325
• DOI: http://doi.org/10.4266/acc.2021.00829

Abstract

Propofol is widely used to sedate agitated patients in intensive care units. However, it can cause a rare but fatal complication, propofol-related infusion syndrome (PRIS). The pathophysiology of PRIS is not clear, and there is no definitive diagnosis and treatment. We report a successfully treated case of PRIS in a critically ill patient receiving low-dose propofol infusion. A 59-year-old male patient complaining of sudden chest pain repeatedly collapsed in an ambulance and the emergency room, and veno-arterial extracorporeal membrane oxygenation was delivered. He was diagnosed with a total occluded left anterior descending coronary artery in coronary angiography. On day 20, he showed arrhythmia, increased creatinine kinase (CK), and increased CK-MB and troponin I, accompanied by unstable hemodynamic status despite high-dose vasopressors. He was administered propofol for 20 days at an average dose of 1.3 mg/kg/hr owing to issues with agitation and ventilator synchrony. We strongly suspected PRIS and immediately discontinued propofol infusion, and he was successfully treated with aggressive supportive care. PRIS can occur in patients administered propofol for a prolonged period at low doses. Thus, clinicians should use propofol with caution for PRIS and change to alternative sedatives for long-term sedation.

Keyword

carnitine; extracorporeal membrane oxygenation; propofol; propofol infusion syndrome

Reference

1. Hatch DJ. Propofol-infusion syndrome in children. Lancet. 1999; 353:1117–8.

2. Roberts RJ, Barletta JF, Fong JJ, Schumaker G, Kuper PJ, Papadopoulos S, et al. Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study. Crit Care. 2009; 13:R169.

3. Cremer OL, Moons KG, Bouman EA, Kruijswijk JE, de Smet AM, Kalkman CJ. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet. 2001; 357:117–8.

4. Mirrakhimov AE, Voore P, Halytskyy O, Khan M, Ali AM. Propofol infusion syndrome in adults: a clinical update. Crit Care Res Pract. 2015; 2015:260385.

5. Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth. 2019; 122:448–59.

6. Fodale V, La Monaca E. Propofol infusion syndrome: an overview of a perplexing disease. Drug Saf. 2008; 31:293–303.

7. Wolf A, Weir P, Segar P, Stone J, Shield J. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet. 2001; 357:606–7.

8. Schenkman KA, Yan S. Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy. Crit Care Med. 2000; 28:172–7.

9. Zhou W, Fontenot HJ, Liu S, Kennedy RH. Modulation of cardiac calcium channels by propofol. Anesthesiology. 1997; 86:670–5.

10. Park SY, Kim EG, Park HP. Propofol-related infusion syndrome in an adult patient using propofol coma therapy to control intracranial pressure. Korean J Crit Care Med. 2013; 28:234–8.

11. Uezono S, Hotta Y, Takakuwa Y, Ozaki M. Acquired carnitine deficiency: a clinical model for propofol infusion syndrome? Anesthesiology. 2005; 103:909.

12. Moriyama T, Kiyonaga N, Ushikai M, Kawaguchi H, Horiuchi M, Kanmura Y. Effects of L-carnitine on propofol-induced inhibition of free fatty acid metabolism in fasted rats and in vitro. Open J Anesthesiol. 2018; 8:147–58.